Without the benefit of examination and testing, coloplast is precluded from commenting on the condition of the device or the cause of the occurrence.Should additional facts prompt us to alter or supplement any information or conclusions contained in the original mdr or in any prior supplemental reports, a follow-up report will be submitted.
|
We have been informed about a defect product, on a ureteric catheter.According to the complaint description lot number and sample are available.The quality databases reveal other complaints for the lot number 8742583 and a corrective and preventive action is ongoing capa-000054 "wrong product in packaging ac5405 instead of acp205" opened on april 2023.Documentary and traceability investigation showed a labelling issue into intermediate product at the production and logistics level, ac540580 was labeled as acp20580 and conduct to this packaging error.A risk evaluation was conducted through capa to analyze the situation and showed that risks are adequately controlled and reduced as far as possible in the state of art.Based on this, the residual risks are adequately controlled and reduced as far as possible, and the residual risk associated with the use of the product are acceptable when weighed against the benefits to the patient/user.It is concluded that the risks identified are still acceptable and considered as safe.
|